# BEAM — slm-full-gpu

## Metadata

ticker: BEAM
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 31bdf0498bdfbc1bd59156a04bfcb47fd8deeffd48d9f503702ee4b80d0b5a22
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 675, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.964, "latency_s_total": 10.964, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 442, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 8.688, "latency_s_total": 8.688, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 125, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.523, "latency_s_total": 4.523, "parse_failure": 0, "prompt_tokens": 695, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 183, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.325, "latency_s_total": 5.325, "parse_failure": 0, "prompt_tokens": 689, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 165, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.13, "latency_s_total": 5.13, "parse_failure": 0, "prompt_tokens": 514, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 150, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.929, "latency_s_total": 4.929, "parse_failure": 0, "prompt_tokens": 755, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 979, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.775, "latency_s_total": 10.775, "parse_failure": 0, "prompt_tokens": 1624, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.5,
  "currency": "USD",
  "market_cap": 2530547712.0,
  "forward_pe": -5.1672826,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin": -0.55449003,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for BEAM, the key takeaways regarding the company's financial position, operational status, and future outlook are as follows:

**Financial Performance and Losses**
*   **Significant Operating Losses:** The company has incurred substantial losses since inception, with net losses of $80.0 million (2025), $376.7 million (2024), and $132.5 million (2023). As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **No Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. There is no guarantee that future revenues will be sufficient to offset operating expenses.
*   **Cash Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities, which is believed to be sufficient to fund operations and capital expenditures for at least the next 12 months.

**Capital Requirements and Funding Risks**
*   **Need for Additional Funding:** The company will require substantial additional capital to continue research and development, expand clinical trials, and potentially commercialize products. Operating expenses are expected to increase significantly.
*   **No Committed Capital Sources:** Aside from a credit facility with Sixth Street Lending Partners, the company has no committed external source of additional capital.
*   **Consequences of Funding Shortfalls:** If the company cannot raise capital on acceptable terms or in sufficient amounts, it may be forced to delay, reduce, or eliminate research programs, product development, or commercialization efforts. This could also lead to the termination of license and collaboration agreements.
*   **Dilution and Restrictions:** Raising additional capital through equity or debt may cause dilution to existing stockholders and impose restrictive covenants on the company’s operations.

**Operational Status and Development Challenges**
*   **Early-Stage Development:** Founded in 2017, the company is an early-stage entity with a short operating history. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or manufactured a commercial-scale medicine.
*   **High Risk of Failure:** Many product candidates are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not demonstrated an ability to successfully commercialize products.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which resulted in the pausing or elimination of certain pipeline programs to reduce costs.

**Future Outlook**
*   **Uncertain Timeline:** It typically takes 10 to 15 years to develop a new medicine. The company cannot predict when it will become profitable, if ever, due to the numerous risks and uncertainties associated with developing base editing product candidates.
*   **Commercialization Hurdles:** Even if product candidates are approved, the company faces challenges in manufacturing, marketing, and distributing medicines, as well as satisfying post-marketing requirements. Commercial revenues are not expected for years, if ever.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Losses and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability.
*   **Requirement for Additional Funding:** Substantial additional funding is required to support continuing operations, including research and development, clinical trials, and potential commercialization. If capital cannot be raised when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research and product development programs or future commercialization efforts.
*   **Lack of Commercial History and Product Approval:** The company has not completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines. It has not yet demonstrated the ability to manufacture commercial-scale medicines or conduct necessary sales and marketing activities.
*   **Limited Operating History:** The company has a short operating history in the rapidly evolving base editing and gene editing fields, making it difficult to evaluate its technology, industry, or predict future performance.
*   **Execution Risks:** Success depends on challenging activities such as identifying product candidates, completing preclinical and clinical studies, obtaining regulatory approval, and manufacturing and marketing medicines. Failure in these areas could materially harm the business, operating results, and financial condition.
*   **Past Strategic Changes:** The company has previously delayed, reduced, or eliminated research and product development programs to decrease operating expenses, such as the portfolio reprioritization and strategic restructuring announced in October 2023.
*   **Dependence on Collaborations and Licenses:** Future capital requirements and business objectives depend on the success of license agreements and collaborations. Failure to meet payment or other obligations under these agreements could lead to their termination.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $24.50, reflecting a market capitalization of approximately $2.53 billion. The company reported revenue of $156.04 million but remains unprofitable, with a net income of -$86.52 million and a negative profit margin of -55.45%. Consequently, the forward P/E ratio is negative, indicating that earnings expectations do not yet support a positive valuation multiple. This financial profile highlights the inherent risks associated with its pre-profitability stage in the biotechnology sector.

### Recent Developments

Beam Therapeutics Inc. (BEAM) is currently trading at $24.50, reflecting a market capitalization of approximately $2.53 billion despite reporting a net loss of $86.5 million and a negative profit margin of -55.45%. The company’s forward P/E ratio of -5.17 underscores the market's expectation of continued near-term losses as it operates within the competitive biotechnology sector. Investors should closely monitor the upcoming 10-Q filing scheduled for August 4, 2026, which will detail new risk factors and financial performance updates that could significantly impact stock volatility. With the stock currently near its 52-week low of $20.23, any positive clinical or regulatory developments could serve as a catalyst for recovery, while persistent operational risks remain a key concern for long-term valuation.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for 2025, bringing its accumulated deficit to $1.6 billion, while maintaining a robust cash position of $1.2 billion sufficient to fund operations for at least the next 12 months. The company remains in an early-stage development phase with no commercial products or pivotal trial completions, necessitating substantial additional capital to sustain its research and expansion efforts. Although no external capital sources are currently committed beyond a Sixth Street credit facility, management warns that failure to secure funding could force delays or terminations of key pipeline programs. Consequently, the company expects to incur significant operating losses for the foreseeable future and may never achieve profitability.

### Risk Factors

*   **Significant Financial Losses and Capital Requirements:** The company has incurred substantial operating losses (accumulated deficit of $1.6 billion as of Dec 2025) and expects to continue burning cash; failure to secure additional funding on attractive terms could force delays or cancellations of development programs.
*   **Pre-Revenue Status and Regulatory Uncertainty:** BEAM has no commercial history, has not completed pivotal trials, and has not obtained marketing approvals, meaning it has not yet demonstrated the ability to manufacture commercial-scale medicines or generate revenue.
*   **Execution and Strategic Risks:** Success depends on navigating complex R&D, manufacturing, and regulatory hurdles, with past portfolio reprioritizations highlighting the risk that failure in any stage of development could materially harm the business.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. (BEAM) operates as a pre-revenue gene editing company with a market capitalization of approximately $2.53 billion, despite reporting a negative profit margin of -55.45% and an accumulated deficit of $1.6 billion. The stock is notable for trading near its 52-week low of $20.23 while holding a cash position of $1.2 billion that provides a runway of at least 12 months to fund ongoing operations. The single most important near-term variable is the company’s ability to secure additional capital or demonstrate clinical progress, as failure to do so could force the termination of key pipeline programs.

### Outlook
The directional outlook for Beam Therapeutics is cautiously neutral, characterized by a high-risk, high-reward profile typical of early-stage biotechnology firms. The primary tailwind is the company’s substantial cash reserve of $1.2 billion, which mitigates immediate existential risk and provides a buffer to advance its pipeline without immediate dilution. However, significant headwinds persist, including the absence of commercial products, the lack of pivotal trial completions, and the inevitability of continued operating losses. Investors should closely monitor the trajectory of cash burn relative to the 12-month runway and any updates regarding the Sixth Street credit facility or new capital raises. A shift toward a more constructive view would require tangible evidence of clinical efficacy or regulatory momentum that validates the long-term value of the gene-editing platform, whereas any indication of funding gaps or program terminations would likely weaken the investment thesis.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every quantitative, forward-looking, and specific factual claim in the **Executive Summary** and **Outlook** sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "market capitalization of approximately $2.53 billion"
LABEL: SUPPORTED
REASON: Source data lists market_cap = 2,530,547,712.0, which rounds to approximately $2.53 billion; also confirmed in the Financial Health pre-written section.

---

CLAIM: "negative profit margin of -55.45%"
LABEL: SUPPORTED
REASON: Source data lists profit_margin = -0.55449003, which equals -55.449%, rounding to -55.45%; confirmed in the Financial Health and Recent Developments pre-written sections.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and SEC Filing Highlights pre-written section both explicitly state the accumulated deficit as of December 31, 2025 was $1.6 billion.

---

CLAIM: "trading near its 52-week low of $20.23"
LABEL: SUPPORTED
REASON: Source data confirms week_52_low = 20.23 and current_price = 24.50; arithmetic check: $24.50 is 21.1% above the 52-week low of $20.23, and the 52-week high is $38.26, placing the stock in the lower third of its range, consistent with "near its 52-week low." The 52-week low figure of $20.23 is explicitly present in the source data.

---

CLAIM: "cash position of $1.2 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "the company held $1.2 billion in cash, cash equivalents, and marketable securities" as of December 31, 2025; also confirmed in the SEC Filing Highlights pre-written section.

---

CLAIM: "provides a runway of at least 12 months to fund ongoing operations"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states the $1.2 billion cash position "is believed to be sufficient to fund operations and capital expenditures for at least the next 12 months"; confirmed in the SEC Filing Highlights pre-written section.

---

CLAIM: "failure to do so could force the termination of key pipeline programs"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state that failure to raise capital "may be forced to delay, reduce, or eliminate research programs" and could lead to "termination of license and collaboration agreements"; the SEC Filing Highlights pre-written section also states this directly.

---

## OUTLOOK

---

CLAIM: "substantial cash reserve of $1.2 billion"
LABEL: SUPPORTED
REASON: Identical to the cash position claim above; explicitly stated in the RAG SEC Highlights and SEC Filing Highlights pre-written section as $1.2 billion in cash, cash equivalents, and marketable securities as of December 31, 2025.

---

CLAIM: "mitigates immediate existential risk and provides a buffer to advance its pipeline without immediate dilution"
LABEL: INFERENCE
REASON: The $1.2 billion cash runway of at least 12 months is explicitly sourced; the inference that this mitigates "immediate existential risk" and avoids "immediate dilution" is a direct logical derivation from the stated sufficiency of the cash position for at least 12 months, with no additional unsourced facts required.

---

CLAIM: "absence of commercial products"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states the company "has not yet completed any pivotal clinical trials, obtained marketing approvals, or manufactured a commercial-scale medicine"; confirmed in the Risk Factors pre-written section.

---

CLAIM: "lack of pivotal trial completions"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state the company "has not completed any pivotal clinical trials."

---

CLAIM: "inevitability of continued operating losses"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights states "The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability"; confirmed in the SEC Filing Highlights and Risk Factors pre-written sections.

---

CLAIM: "monitor the trajectory of cash burn relative to the 12-month runway"
LABEL: SUPPORTED
REASON: The 12-month runway figure is explicitly sourced from the RAG SEC Highlights; the directional watch-item is a logical restatement of the disclosed cash sufficiency period and the disclosed expectation of continued operating losses.

---

CLAIM: "any updates regarding the Sixth Street credit facility or new capital raises"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly names "a credit facility with Sixth Street Lending Partners" as the only committed external capital source; the SEC Filing Highlights pre-written section also references it by name.

---

CLAIM: "A shift toward a more constructive view would require tangible evidence of clinical efficacy or regulatory momentum that validates the long-term value of the gene-editing platform"
LABEL: INFERENCE
REASON: No specific clinical milestone, trial name, regulatory deadline, or numeric threshold is cited; this is a directional inference derivable from the disclosed facts that the company has no pivotal trial completions and no marketing approvals, making clinical/regulatory progress the logical catalyst — no unsourced specific figures are asserted.

---

CLAIM: "any indication of funding gaps or program terminations would likely weaken the investment thesis"
LABEL: INFERENCE
REASON: This is a directional restatement directly derivable from the explicitly sourced risk that failure to secure capital could force delays or terminations of pipeline programs, as stated in the RAG SEC Highlights and Risk Factors; no additional unsourced facts are required.

---

### Summary Table

| # | Claim | Label |
|---|-------|-------|
| 1 | Market cap ~$2.53 billion | SUPPORTED |
| 2 | Profit margin -55.45% | SUPPORTED |
| 3 | Accumulated deficit $1.6 billion | SUPPORTED |
| 4 | Trading near 52-week low of $20.23 | SUPPORTED |
| 5 | Cash position $1.2 billion | SUPPORTED |
| 6 | Runway of at least 12 months | SUPPORTED |
| 7 | Failure could force termination of pipeline programs | SUPPORTED |
| 8 | Cash reserve $1.2 billion (Outlook) | SUPPORTED |
| 9 | Mitigates existential risk / avoids immediate dilution | INFERENCE |
| 10 | Absence of commercial products | SUPPORTED |
| 11 | Lack of pivotal trial completions | SUPPORTED |
| 12 | Inevitability of continued operating losses | SUPPORTED |
| 13 | Monitor cash burn vs. 12-month runway | SUPPORTED |
| 14 | Sixth Street credit facility watch-item | SUPPORTED |
| 15 | Clinical efficacy/regulatory momentum as constructive catalyst | INFERENCE |
| 16 | Funding gaps/program terminations weaken thesis | INFERENCE |

**No UNSUPPORTED claims were identified.** All quantitative figures are traceable to the source data or pre-written sections, and all forward-looking directional statements are either directly sourced or cleanly derivable from sourced facts.
